Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acamprosate in adults with Prader-Willi syndrome
ACTRN12619001779167Phase 2Recruiting
- Sponsor
- The University of Sydney
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of acamprosate in Prader-Willi syndrome (PWS) (2 arms), sponsored by The University of Sydney. Primary endpoint: Brain GABA levels. Started Sep 2023; status: recruiting.
02
Drugs
acamprosate
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on ACTRN12619001779167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001779167.